Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Iovance Biotherapeutics's Lifileucel?
Lifileucel is a cell therapy commercialized by Iovance Biotherapeutics, with a leading Phase II program in Cervical Cancer. According to...
Lifileucel by Iovance Biotherapeutics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Lifileucel by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of Iovance Biotherapeutics's Lifileucel?
Lifileucel is a cell therapy commercialized by Iovance Biotherapeutics, with a leading Phase II program in Giant Cell Tumor Of...